SARS‐CoV‐2 mRNA vaccine‐associated fixed drug eruption

Mintoff, Dillon; Pisani, David; Betts, Alexandra; Scerri, Lawrence

doi:10.1111/jdv.17390

Cited by 20 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical corticosteroids improved pruritus and redness. A skin biopsy revealed a lichenoid interface dermatitis confirming the clinical diagnosis of a fixed drug eruption [15]. Three similar cases have been reported in middle-aged women after the second shot of BNT162b2, one with vesiculation [16].…”

Section: Allergy Except Anaphylaxismentioning

confidence: 54%

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Wollina

Chiriac

Kocic

et al. 2021

Wien Med Wochenschr

View full text Add to dashboard Cite

Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV‑2) has become a major tool in the battle against the coronavirus disease 2019 (COVID-19) pandemic. Numerous products have been developed and more are to come. Vaccination success varies greatly between different countries. There are a number of different vaccine types, such as mRNA, DNA vaccines, adenovirus vector vaccines, and full-length spike protein nanoparticles with a special matrix. The different types may also cause a different spectrum of adverse events. With mass vaccination, post-marketing surveillance for product safety becomes increasingly important. In this review, we discuss possible hypersensitivity and cutaneous adverse events related to SARS-CoV‑2 vaccination—from local reactions like COVID arm to systemic and severe reactions like anaphylaxis. Vaccination may also induce or exacerbate preexisting disorders such as herpes zoster infection. This review should provide information to tailor, whenever possible, vaccination to patients’ needs. It is a contribution to patient safety as well. There is general consensus that the benefits of SARS-CoV‑2 vaccination currently outweigh the risks of possible adverse events.

show abstract

Section: Allergy Except Anaphylaxismentioning

confidence: 54%

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Wollina

Chiriac

Kocic

et al. 2021

Wien Med Wochenschr

View full text Add to dashboard Cite

show abstract

“…One case of Sweet syndrome accompanied by acute encephalitis was described in a 77-year-old man after the first dose of the mRNA-1273 vaccine [55]. There are sporadic reports of fixed drug eruptions [6,18,56]. Two middle-aged women developed a rosacea-like eruption 4 to 5 days after Ad26.CoV2.S and BNT162b2 vaccination [57].…”

Section: Other Dermatosesmentioning

confidence: 99%

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

Many patients are receiving SARS-CoV-2 vaccinations, which have been associated with a variety of adverse effects. Cutaneous adverse reactions to SARS-CoV-2 vaccinations have been progressively reported, but they have not been reviewed according to their morphological clinical patterns. The objective of this review was to summarize the existing data concerning the cutaneous adverse reactions following SARS-CoV-2 vaccines and group them according to common morphological and pathogenetic patterns. We reviewed the English language literature up to 15 August 2021, using predefined keywords to identify the relevant studies evaluating cutaneous adverse reactions associated with SARS-CoV-2 vaccines. We search for recurrent morphological patterns sharing clinical signs and symptoms and physio-pathological mechanisms. Timing to onset following the first or booster dose of the vaccine, predisposing conditions, therapeutic management, and outcome were also collected. Among the dermatological manifestations associated with SARS-CoV-2 vaccinations, we distinguished: (1) new onset reactions and (2) flares of preexisting dermatoses. The most common were injection site reactions, affecting 30–70% and generally mild or moderate. Small case series or single case reports included filler reactions, exanthemas, vascular lesions, urticaria, eczematous dermatitis, autoimmune bullous reactions, and severe cutaneous adverse reactions. In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported. The cutaneous reactions were generally mild, self-limiting, and resembled common cutaneous drug eruptions and/or COVID-19 skin manifestations.

show abstract

“…Now, with the COVID‐19 vaccination effort being ramped up around the world, dermatologists also need to become aware of its considerations in patients with skin diseases, as well as possible vaccine‐related cutaneous reactions 3 …”

Section: Introductionmentioning

confidence: 99%

COVID ‐19 vaccines: What dermatologists should know?

Ayatollahi

Hosseini

Firooz

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

As COVID‐19 vaccination has started worldwide to control this pandemic, dermatologists may face various challenges with these new vaccines. In this manuscript, we review different types of available COVID‐19 vaccines and their various production platforms. Vaccination considerations in patients with skin diseases, especially those using immunomodulatory drugs will be presented. Finally, adverse cutaneous reactions of COVID‐19 vaccines will be reviewed.

show abstract

SARS‐CoV‐2 mRNA vaccine‐associated fixed drug eruption

Cited by 20 publications

References 10 publications

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

COVID ‐19 vaccines: What dermatologists should know?

Contact Info

Product

Resources

About